Multidrug-resistant (MDR) myeloma patients failing chemotherapy may express P-glycoprotein (PGP), which serves as an efflux pump protecting the neoplastic cells. Unknown is whether PGP expression might relate to prior cytotoxic drug exposure. To address this question, we studied 106 consecutive bone marrow samples from 104 myeloma patients with samples studied either before or after therapy and at the time of relapse. We performed an established immunocytochemical assay of PGP using an MDR-1 -specific monoclonal antibody and correlated PGP status with prior chemotherapy dosage. Myeloma patients with no prior therapy had a low incidence of PGP expression (6%. 3/47), whereas those receiving chemotherapy had a significantly higher incidence (43%. 21/49) (P < .0001). A substantially higher incidence of PGP expression (50%. 83%, respectively) occurred when the total vincristine dose exceeded 20 mg and when doxorubicin exceeded 340 mg. In the 11 patients who received both high vincristine and doxorubicin dosages (220 mg, >340 mg total dose) there was 100% LINICAL STUDIES have established that P-glycoprotein C (PGP) expression occurs in plasma cell myeloma patients with clinical evidence of multidrug resistance (MDR).I4 PGP is an integral membrane protein that serves as an efflux pump protecting the cells from lethal natural product anticancer drug accumulation.' Verapamil competitively inhibits this mechanism by binding to PGP and has resulted in clinical reversal of MDR in some patients with or lymphoma.*.' Reports to date have focused on end-stage therapyfailure patients and have not established in which clinical context PGP expression occurs in multiple myeloma.23738 Accordingly, we organized a study of myeloma patients at various stages of disease to determine the incidence of PGP in bone marrow (BM) samples. Our recent methodologic study comparing PGP assays showed that an optimized immunocytochemical method, using BM aspirate cytospin preparations, allows sensitive and specific detection in clinical samp l e~.~ In the current study, PGP expression was examined in nontreated versus treated patients to determine whether the incidence of PGP expression in the tumor cells. These data provided the basis for a predictive mathematical model from which dose-related PGP expression normograms were generated. Time with myeloma for PGP-negative patients (mean 33 months) had overlapping confidence limits with PGP-positive patients (mean 42 months), suggesting that disease duration was not a significant variable. PGP expression did not correlate with other clinical factors or immunophenotypic factors. Our findings indicate a strong correlation between PGP expression in myeloma and past chemotherapy in myeloma, in particular, related to prior exposure to the natural product agents vincristine and doxorubicin. Additionally, the proportion of PGP-positive plasma cells was significantly higher in the doxorubicintreated patients than the nondoxorubicin-treated patients (87.7% v 65.17%; P = .013). Combined high vincristine and doxorubicin total dosage appear highly predictive of PGP expression. specific type and amount of drug exposure might be relevant to PGP expression. Clinical factors and immunophenotypic status were also examined as possible determinants of PGP expression. In this 2-year study, we established that PGP expression in myeloma is largely correlated with high total dosages of combined natural product therapy. This suggests that PGP expression in multiple myeloma could represent, at least in part, a therapy-adapted phenotypic change associated with the clinical development of MDR.
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MATERIALS AND METHODS
We prospectively studied 106 consecutive BM biopsy samples and aspirates from 104 myeloma patients. These marrow samples were submitted to the Arizona Cancer Center's Myeloma Repository over a 2-year period. For this specific analysis, BM specimens were obtained from patients either before or after therapy at the time of clinical relapse with marrow showing greater than 20% plasmacytosis. Submissions included both Arizona (n = 64) and Southwest Oncology Group (SWOG) (n = 40) patients entering the SWOG 8624 myeloma protocol for previously untreated patients and SWOG 8900 for patients in relapse from prior chemotherapy.
Immunoperoxidase staining for PGP. Marrow aspirates were separated using Ficoll-Hypaque (Organon Teknika, Durham, NC) separation media, resuspended in RPMI and then applied to glass slides using a cytospin (Shandon, Sawyer, PA), as described previously.'~lo Simultaneous control cytospin slides used a myeloma cell line "button" comprised of 1/3 each mixtures of PGP-negative (8226-sensitive), PGP low-level resistance (8226-Dox 6), and PGP high-level resistance (8226 Dox 40) myeloma cells. These variable PGP-expressive myeloma cell lines (8226 S, 6,40) were derived and maintained at the Arizona Cancer Center.'," Slides were fixed in icecold acetone, air dried, and then stored at -180°C until study. An optimized immunocytochemistry assay was applied using a biotinylated secondary antibody [F(ab,)'], a biotin-avidin bridge, and immunoperoxidase and diaminobenzidine (DAB) as the chromogen. All samples were studied with the MDR-I-specific murine monoclonal antibody (MoAb) JSB-1'' as the primary antibody. This lgGl antibody was used at 5 pg/pL with appropriate isotype-matched negative controls. A subset of samples from 28 patients were also stained with anti-PGP MoAb C219.I' Although we found high concordance with both antibodies (93% agreement: 26/28 cases), all data thereafter were analyzed with regard to JSB-1 reactivity because this antibody has been established as MDR-1 specific via transfection studies.14 Using the same biotin-avidin, DAB method detection of additional antigens was studied using the following primary antibodies: was sought in cases that were difficult to interpret. Cases with disagreements were judged "questionable" and dropped from analysis. Samples were scored as "negative" when all plasma cells were negative and positive when any plasma cells stained. By microscopic examination of plasma cells and counting, 22 of 24 cases showed membrane staining in greater than 30% plasma cells, and 2 cases were in the 5% to 10% positive range (details in Results section). Among the 106 BM samples, 10 samples were either insufficient or not interpretable for PGP staining, while the remaining 96 samples were satisfactory on both accounts.
Immunocytochemistry results were analyzed in relation to known treatment variables. A two-tailed Fisher exact test was used to analyze the association of therapy and PGP expression. To test the predictive value of the combined effect of two drugs over a range of doses, in relation to PGP expression, a three-dimensional stepwise logistic regression analysis was used. A Wilcoxon two-sample rank sum test was used both to test the effect of time with disease on PGP expression and to compare the FGP positive percentages for the nondoxorubicin and doxorubicin-treated subjects.
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RESULTS
Among the evaluable 96 specimens, the overall incidence of PGP expression was 25% (24/96). As shown in Fig 1, the patients with no prior therapy had a low incidence of PGP positivity (6%, 3/47), whereas those receiving therapy had a significantly higher incidence (43%, 2 1/49) (P < .OW 1). Also shown in Fig 1, there was an ascending scale of PGP expression corresponding with increased exposure to therapy with natural product drugs (vincristine and doxorubicin).
Considering that the increased PGP incidence in the specific patient therapy groups in Fig 1 might relate to the cumulative dose of vincristine and doxorubicin, we further analyzed data for the 40 patients who had been administered either one or both drugs. As shown in Fig 2, groups C (9 patients) and D (31 patients) could be further stratified by PGP expression based on the total cumulative dose of vincristine or doxorubicin administered. Figure 2 shows a substantially higher incidence of PGP expression when the total cumulative vincristine dose exceeded 20 mg and when doxorubicin exceeded 340 mg. While this effect was statistically significant (P < .001), the patients in group D (the doxorubicin-treated patients) typically also received vincristine, requiring correction for a combined vincristine/doxorubicin effect. This is shown in Fig 3, wherein the patients receiving low total dosage vincristine/doxorubicin (<20 mg/340 mg) had a low PGP expression (12%), whereas there was a 100% incidence of PGP expression in the 1 1 patients who had received both high total vincristine/doxorubicin dosages (>20 mg and >340 mg, respectively; P < .0001). Patients receiving either high doses of either vincristine or doxorubicin, but not both, had an intermediate incidence (53%).
The close correspondence in Fig 3 between increasing PGP incidence and increasing vincristine and doxorubicin dosage suggested that a predictive mathematical model of PGP expression related to PGP expression related to vincristine/ doxorubicin dosage could be developed. To account for the combined effect of vincristine and doxorubicin a three-dimensional logistic regression model of PGP incidence was used (Fig 4) . Each vertical mark in Fig 4A portrays For combined dosages were predictive of very low PGP expression, while the high combined dosages were very predictive of high PGP expression. These data points may be transformed or smoothed into an isotherm form as shown in Fig  4B, giving geometric form to the analysis. As shown in Fig 4B, doxorubicin dosages greater than 340 mg combined with vincristine greater than 20 mg appear to result in a high plateau of predicted PGP expression. Using the data summarized in Table 1 , nomograms of likely PGP expression can be developed wherein the probability of PGP for a given patient situation can be related to total cumulative dose of vincristine plus doxorubicin. For example, if a patient has been administered 2 mg of vincristine and 100 mg of doxorubicin, the probability of expressing PGP is 0.12. On the other hand, a patient who has been administered 40 mg vincristine and 400 mg of doxorubicin before biopsy has a high probability (0.91) of expressing PGP.
Among the patients with positive PGP staining, we compared the actual percentage of PGP positive myeloma cells from nondoxorubicin-treated subjects and those treated with doxorubicin. Patients who had received doxorubicin therapy had a significantly higher proportion of PGP-positive plasma cells compared with the nondoxorubicin-treated group. The mean for the nondoxorubicin group was 65.2% with a standard deviation of 3 1.7%. The mean for the doxorubicin group was 87.7% PGP+ plasma cells with a standard deviation of 26.6%. A Wilcoxon two-sample test showed a significant difference between the two groups, P = .O 13.
Aside from drug type and dosage, we considered a relationship between PGP expression and duration of disease. To eliminate variable therapy effects, we chose to study the 31 group D doxorubicin-treated patients as the most uniformly treated group available. Within this group, as shown in Fig 5 , we found the time from diagnosis (in months) to re-biopsy and PGP assay was comparable between the PGPnegative ( 13 patients) and PGP-positive ( I8 patients) group. The PGP-negative patients' time with myeloma (mean 33 months) had overlapping confidence limits with the PGPpositive patients' time with myeloma (mean 42 months). On this basis, disease duration was not a significant (P = .19) variable in determining PGP expression. A further portrayal of time versus doxorubicin dosage is shown in Fig 6, where the mean time with disease was comparable in PGP+ and PGP-patients, whereas a high incidence of PGP appeared when patients were treated with 2300 mg of doxorubicin.
Finally, the same 31 patients in group D, as the most uniformly treated group, were also chosen to study the relationship between PGP expression and other clinical and immunophenotypic factors. As shown in Table 2 , the PGPpositive and -negative subsets appear quite similar with regard to clinical parameters (eg, age, sex, stage) and similar with regard to additional phenotypic properties (eg, immunoglobulin isotype, immature B-cell antigens, myeloid antigen coexpression and proliferative rate). This suggests that PGP expression does not correlate with other clinical or immunophenotypic factors in our doxorubicin-treated group D.
DISCUSSION
Our findings suggest that PGP expression in myeloma is highly correlated with prior exposure to natural product anticancer drugs such as vincristine and doxorubicin. These natural products show an increasing effect on PGP expression with increasing cumulative dose. Newly diagnosed untreated myeloma patients had a low incidence of PGP expression, while patients receiving initial alkylating agents had a slightly increased incidence. In contrast, patients who were administered the natural products doxorubicin and vincristine had a significantly higher incidence.
Further analysis of the patients receiving natural products showed a strong cumulative dosage effect with a PGP incidence of 50% for vincristine greater than 20 mg and 83% PGP expression for doxorubicin greater than 340 mg. Because the latter patients also received vincristine, the combined effect of vincristine and doxorubicin was tested and showed a 100% incidence of PGP expression in the 1 1 patients administered both drugs at high cumulative dose (>20 mg, >340
The observed ascending incidence of PGP expression in the context of ascending vincristine and doxorubicin dosage raised the prospect of a predictive model. Figure 4 depicts a three-dimensional logistic regression model that accounts for combined vincristine and doxorubicin dosages in a matrix fashion and shows in geometric form the increasing probabilities of PGP expression with increased combined dosage. This stepwise logistic regression analysis established that vincristine and doxorubicin total dosage levels are good predictors of the presence or absence of PGP in human myeloma samples. These same values may then be used to construct a nomogram of vincristine and doxorubicin dosages that give PGP expression probab es as shown in Table 1 . While this model assumes independent action of vincristine and doxorubicin, it nonetheless is dependent on data derived from patients receiving incremental dosages of both agents.
We further questioned if time with disease or duration of disease alone might determine PGP incidence. Thus, PGP expression might evolve as a natural phenotypic property independent of therapy dosage, and increased dosage might mg).
For personal use only. on August 29, 2017. by guest www.bloodjournal.org From with VAD the rap^.'^ Because a significant number of these patients were involved in a chemosensitizing trial that altered the disease natural history, we cannot resolve the effect of PGP on myeloma survival. A similar study using cyclosporine A as a chemosensitizer confirmed our observations that MDR can be reversed with chemosensitizers.'6 Prior study by Epstein et all7 had suggested that therapy responsiveness indeed related to the proportion of PGP-positive anaplastic plasma cells in myeloma. The present study did detail the proportion of PGP-positive plasma cells relative to therapy group, finding a significantly higher proportion of PGP-positive plasma cells in the doxorubicin-treated group, suggesting that not only PGP incidence but also PGP proportion correlates with the type of prior therapy.
It is important to recognize that all patients studied had BM aspirates obtained either before treatment or during their course of treatment when they had clinical problems (such as drug resistance) that justified obtaining a BM aspirate. Additionally, based on our screening criteria, patients had to have at least 20% plasma cells in the marrow. Thus, the patients studied were not in remission. Accordingly, our results cannot be considered to indicate that all patients who have 
